Chemours opened lower at $13.56, compared with its previous close of $13.72. In the last trading session, the stock traded between $13.29 and $13.68. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Chemours is now worth
$ 41.20
Resulting in a loss of
$ 58.80 (58.80%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 9 Analysts
Buy
33.33%
Hold
66.67%
Sell
0%
Markets Today
Today's Change
$-0.37 (-2.73%)
Day High
$13.68
Day Low
$13.29
Day Open
$13.56
Prev Close
$13.72
Volume
7,03,588
1W Return
-3.35%
1M Return
-0.37%
3M Return
-9.86%
6M Return
-47.17%
1Y Return
5.50%
Fundamentals
Market Cap ($ Mn)
2,009
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-99.74%
ROCE
-0.14%
EPS (TTM)
$1.30
Investment Returns
1 Week
-3.35%
1 Month
-0.37%
3 Months
-9.86%
6 Months
-47.17%
9 Months
-36.51%
Financials
Quarterly
All values in $ Mn
1.6K
Jun 25
1.5K
Sep 25
1.3K
Dec 25
1.4K
Mar 26
1.6K
Jun 26
1.5K
Sep 26
Updates
12Nov
Chemours faces Dec 7 deadline in securities suit over guidance cut
Lead plaintiff deadline for Chemours class action is Dec 7, 2026. Shares fell 18.63% to $14.59 after guidance cut to $775M-$825M. Suit alleges failure to disclose Opteon channel overstocking from 2025.
Today
5Nov
UBS maintains Neutral on Chemours, cuts price target to $15
UBS analyst Joshua Spector lowered Chemours' price target from $16 to $15. The rating on the stock remains Neutral. No change in investment recommendation accompanied the target cut.
8 days ago
5Nov
Truist maintains buy on Chemours, lowers price target to $18
Truist Securities maintains a Buy rating on The Chemours Company. Price target lowered from $20 to $18. Analyst Peter Osterland issued the revised recommendation.
8 days ago
3Nov
Chemours Q3 Results: Adj. EPS misses estimate at $0.21
Adjusted EPS of $0.21 missed the $0.27 consensus estimate by 22%. Quarterly sales rose 3.01% YoY to $1.540 billion. Sales figures met analyst consensus expectations. EPS increased 5% from $0.20 in the prior-year quarter.
10 days ago
3Nov
Chemours Q4 Results: Sales guidance $1.67B-$1.75B beats $1.42B est
Chemours guides Q4 sales between $1.671 billion and $1.750 billion. Analyst consensus estimate for the quarter was $1.421 billion. The low end of guidance exceeds the estimate by roughly $250 million.
10 days ago
3Nov
Chemours narrows FY26 sales guidance to $5.924B vs $5.917B est
Chemours narrowed FY26 sales guidance to $5.924 billion. Previous guidance range was $5.866 billion to $6.098 billion. New estimate is $7 million above the $5.917 billion analyst consensus.
